Shares of Assembly Biosciences Inc (NASDAQ:ASMB) have earned an average rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $46.33.
ASMB has been the subject of a number of research analyst reports. Robert W. Baird set a $74.00 price objective on shares of Assembly Biosciences and gave the stock a “buy” rating in a research report on Thursday, October 17th. BidaskClub upgraded shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 17th. Chardan Capital reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Thursday, September 19th. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, ValuEngine upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th.
A number of hedge funds and other institutional investors have recently made changes to their positions in ASMB. Bank of Montreal Can increased its position in Assembly Biosciences by 2,084.1% in the 2nd quarter. Bank of Montreal Can now owns 1,922 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,834 shares during the period. Quantamental Technologies LLC boosted its stake in shares of Assembly Biosciences by 16,941.2% in the 2nd quarter. Quantamental Technologies LLC now owns 2,897 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 2,880 shares during the last quarter. Aperio Group LLC bought a new stake in shares of Assembly Biosciences in the 2nd quarter valued at $55,000. Tower Research Capital LLC TRC boosted its stake in shares of Assembly Biosciences by 9,134.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,340 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,293 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in shares of Assembly Biosciences in the 2nd quarter valued at $134,000. Hedge funds and other institutional investors own 81.21% of the company’s stock.
Shares of NASDAQ:ASMB traded down $1.96 during midday trading on Monday, hitting $12.07. The stock had a trading volume of 1,118,100 shares, compared to its average volume of 374,660. The company’s 50-day moving average price is $12.98 and its 200-day moving average price is $13.53. The company has a market capitalization of $377.16 million, a P/E ratio of -3.03 and a beta of 1.58. Assembly Biosciences has a fifty-two week low of $8.13 and a fifty-two week high of $27.60. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.06.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.03). The company had revenue of $4.23 million for the quarter, compared to analyst estimates of $3.45 million. Assembly Biosciences had a negative return on equity of 52.83% and a negative net margin of 647.72%. Research analysts expect that Assembly Biosciences will post -3.75 EPS for the current fiscal year.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Featured Article: Why are percentage gainers important?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.